EYPT — Eyepoint Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $834.67m
- $503.62m
- $46.02m
- 68
- 14
- 81
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20.4 | 34.4 | 36.9 | 41.4 | 46 |
Cost of Revenue | |||||
Gross Profit | 17.7 | 28.6 | 28.8 | 33.1 | 41.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 72 | 72.6 | 90.2 | 143 | 122 |
Operating Profit | -51.7 | -38.2 | -53.2 | -101 | -76.4 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -56.8 | -45.4 | -58.4 | -102 | -70.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -56.8 | -45.4 | -58.4 | -102 | -70.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -56.8 | -45.4 | -58.4 | -102 | -70.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -56.8 | -45.4 | -58.4 | -102 | -70.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.08 | -3.37 | -2.1 | -2.14 | -1.8 |